MEP38008A - Drospirenone for hormone replacement therapy - Google Patents

Drospirenone for hormone replacement therapy

Info

Publication number
MEP38008A
MEP38008A MEP-380/08A MEP38008A MEP38008A ME P38008 A MEP38008 A ME P38008A ME P38008 A MEP38008 A ME P38008A ME P38008 A MEP38008 A ME P38008A
Authority
ME
Montenegro
Prior art keywords
estrogen
drospirenone
hormone replacement
replacement therapy
drsp
Prior art date
Application number
MEP-380/08A
Other languages
English (en)
Croatian (hr)
Inventor
Juergen Hilmann
Ralph Lipp
Rolf Schuermann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP38008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP38008A publication Critical patent/MEP38008A/xx
Publication of ME00292B publication Critical patent/ME00292B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmaceutska kompozicija koja obuhvata kao prvi aktivni sastojak estrogen, kao što je estradiol ili estradiol valerat, u dovoljnim količinama za tretiranje poremećaja i simptoma asociranih sa deficijentima endogenima nivoima estrogena kod žena, i kao drugi aktivni sastojak 6β, 7β; 15 β; 16 β- dimetilen-3-okso-17ά-preg-4-ene-21, 17- karabalakton (drospirenon, DRSP) u dovoljnim količinama da zaštiti ednometrijum od negativnih efekata estrogena korisna, pored drugog, za tretiranje perimenupauzalnih, menopauzalnih i post-menupauzalnih žena. Ova kompozicija može da se upotrebi za terapiju zamjene hormona i može da se primjenjuje kao multi-fazovan farmaceutski preparat. Ova kombinaciona terapija može da obuhvati kontiunalnu, sekvencionalnu ili isprekidanu primjenu, ilči njihove kombinacije, DRSP i estrogen, svaki opciono u mikronizovanom obliku.
MEP-2008-380A 2000-01-18 2001-01-18 Drospirenon za terapiju zamjene hormona ME00292B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (2)

Publication Number Publication Date
MEP38008A true MEP38008A (en) 2011-02-10
ME00292B ME00292B (me) 2011-05-10

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-380A ME00292B (me) 2000-01-18 2001-01-18 Drospirenon za terapiju zamjene hormona

Country Status (30)

Country Link
EP (2) EP1257280B1 (bs)
JP (2) JP5128743B2 (bs)
KR (2) KR100747965B1 (bs)
CN (2) CN101934078A (bs)
AT (2) ATE442147T1 (bs)
AU (3) AU2001225413B2 (bs)
BG (1) BG65849B1 (bs)
BR (1) BR0107683A (bs)
CA (1) CA2394165C (bs)
CY (1) CY1109567T1 (bs)
CZ (1) CZ20022411A3 (bs)
DE (2) DE60113809T2 (bs)
DK (2) DK1257280T3 (bs)
EE (1) EE05533B1 (bs)
ES (2) ES2332226T3 (bs)
HK (2) HK1047248B (bs)
HU (1) HUP0204291A3 (bs)
IL (3) IL150775A0 (bs)
ME (1) ME00292B (bs)
MX (1) MXPA02006613A (bs)
NO (1) NO335570B1 (bs)
NZ (1) NZ520630A (bs)
PL (1) PL201878B1 (bs)
PT (1) PT1611892E (bs)
RS (1) RS52149B (bs)
RU (2) RU2275198C2 (bs)
SI (2) SI1611892T1 (bs)
SK (2) SK287719B6 (bs)
WO (1) WO2001052857A1 (bs)
ZA (2) ZA200206551B (bs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044941A1 (en) * 1999-08-31 2009-04-08 Bayer Schering Pharma AG Multiple-phase formulation of drospirenone and estradiol as a contraceptive
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
PT1482948E (pt) * 2002-03-11 2006-11-30 Janssen Pharmaceutica Nv Terapia de substituição hormonal contínua com progestogénio inibidor de sulfatase
RS93804A (sr) * 2002-04-26 2006-10-27 Schering Aktiengesellschaft Lečenje hipertenzije kod žena koje primaju terapiju izmene hormona
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
JP2006508945A (ja) * 2002-11-05 2006-03-16 シエーリング アクチエンゲゼルシャフト 抗−アルドステロン性プロゲスチンを用いての心血管保護
PT1748756E (pt) 2004-03-10 2009-07-20 Bayer Schering Pharma Ag Composições compreendendo drospirenona molecularmente dispersa
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
EP1954240A2 (en) * 2005-07-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
US20130140210A1 (en) * 2010-04-15 2013-06-06 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
AU2011240102B2 (en) 2010-04-15 2015-07-23 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for HRT
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AU2012331089A1 (en) 2011-11-04 2014-05-22 Bayer Intellectual Property Gmbh 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17beta-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
CN116077455A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN110809473A (zh) 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
WO1998004269A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP2044941A1 (en) * 1999-08-31 2009-04-08 Bayer Schering Pharma AG Multiple-phase formulation of drospirenone and estradiol as a contraceptive

Also Published As

Publication number Publication date
RU2402331C2 (ru) 2010-10-27
RU2002122113A (ru) 2004-03-10
ZA200601285B (en) 2008-01-08
EP1611892A2 (en) 2006-01-04
DK1611892T3 (da) 2009-11-02
BG106915A (bg) 2003-04-30
HUP0204291A3 (en) 2003-05-28
AU2005209600B2 (en) 2008-08-07
JP2003520239A (ja) 2003-07-02
KR20020088066A (ko) 2002-11-25
AU2005209600A1 (en) 2005-09-29
CN101934078A (zh) 2011-01-05
NZ520630A (en) 2004-09-24
CY1109567T1 (el) 2014-08-13
KR100913910B1 (ko) 2009-08-26
YU54602A (sh) 2006-01-16
AU2001225413B2 (en) 2005-06-23
CA2394165A1 (en) 2001-07-26
IL150775A (en) 2008-08-07
DE60113809T2 (de) 2006-06-22
JP5128743B2 (ja) 2013-01-23
RU2005140938A (ru) 2007-07-10
ES2247054T3 (es) 2006-03-01
IL150775A0 (en) 2003-02-12
EP1611892B1 (en) 2009-09-09
KR100747965B1 (ko) 2007-08-08
EP1257280A1 (en) 2002-11-20
WO2001052857A1 (en) 2001-07-26
JP2009120615A (ja) 2009-06-04
MXPA02006613A (es) 2003-10-15
PL356987A1 (en) 2004-07-12
PT1611892E (pt) 2009-11-20
ES2332226T3 (es) 2010-01-29
ME00292B (me) 2011-05-10
SI1257280T1 (sl) 2006-02-28
ZA200206551B (en) 2006-04-29
KR20070051956A (ko) 2007-05-18
HK1047248A1 (en) 2003-02-14
CA2394165C (en) 2010-04-13
SK10322002A3 (sk) 2003-03-04
DK1257280T3 (da) 2005-12-12
BR0107683A (pt) 2002-11-12
EP1611892A3 (en) 2006-02-01
BG65849B1 (bg) 2010-03-31
PL201878B1 (pl) 2009-05-29
SK287719B6 (en) 2011-07-06
NO335570B1 (no) 2014-12-29
DE60139907D1 (de) 2009-10-22
HK1082433A1 (en) 2006-06-09
CN1395488A (zh) 2003-02-05
IL191131A0 (en) 2008-11-03
NO20022966L (no) 2002-09-18
IL191131A (en) 2010-12-30
CZ20022411A3 (cs) 2003-02-12
ATE442147T1 (de) 2009-09-15
SK288129B6 (sk) 2013-10-02
EE200200401A (et) 2003-10-15
HUP0204291A2 (hu) 2003-04-28
ATE305789T1 (de) 2005-10-15
EE05533B1 (et) 2012-04-16
EP1257280B1 (en) 2005-10-05
HK1047248B (zh) 2005-12-30
AU2541301A (en) 2001-07-31
RU2275198C2 (ru) 2006-04-27
NO20022966D0 (no) 2002-06-20
DE60113809D1 (de) 2006-02-16
JP5563227B2 (ja) 2014-07-30
RS52149B (sr) 2012-08-31
SI1611892T1 (sl) 2010-01-29

Similar Documents

Publication Publication Date Title
MEP38008A (en) Drospirenone for hormone replacement therapy
IL149448A0 (en) New topical estrogen-progestogen compositions with a systemic effect
RS50262B2 (sr) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
KR20120107492A (ko) 프로게스틴/에스트라디올 경피 젤
KR20090080989A (ko) 여성 리비도의 유지 및/또는 증가를 위한 경구 치료요법을 위한 디에노게스트와 조합된 에스트라디올 발레레이트 또는 17β-에스트라디올의 용도
Samsioe Transdermal hormone therapy: gels and patches
EA200301022A1 (ru) Гормональная заместительная терапия
EE05259B1 (et) Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks
HRP20020258B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
HRP20070360A2 (en) Pharmaceutical compositions comprising drospirenone
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
SI20851B (sl) Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH)
PE20010665A1 (es) Una composicion farmaceutica de drospirenona y etinilestradiol para ser usada como anticonceptivo
UY26539A1 (es) Drospirenona para terapia de reemplazo de hormonas.
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti